The federal government has decided to intervene in a whistleblower lawsuit that accuses a Tennessee health system of paying Memphis-area cancer physicians for referrals that allegedly generated about $70 million a year in profits for the health system from billings
…
UPDATE Thursday, March 24, 2022, 2:10 p.m.—A Gilead spokesperson disputed AIDS Healthcare Foundation’s statement that, under Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments, the company will give 340B discounts to covered entities only
…
Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.
BMS posted the refund notice on the U.S. Health Resources and Services Administration
…
California health centers told a federal judge last week that the state’s arguments for dismissing the centers’ lawsuit to reverse a new state Medicaid policy that deprives them of millions of dollars in 340B drug reimbursement lack merit.
Community Health
…
Yesterday, we broke the news that Johnson & Johnson announced conditions on 340B drug sales to hospitals on a host of pharmacy inventory staples including immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders, pulmonary
…
Requiring drug manufacturers “to sell to contract pharmacies at the 340B discount is price-fixing,” an influential source of model bills for conservative state lawmakers says in a new post on its website.
“Legislators understandably worry about the cost of prescription
…
Nebraska Gov. Pete Ricketts (R) signed legislation last week to protect 340B covered entities and their contract pharmacies from discrimination by pharmacy benefit managers.
Legislative Bill 767 makes Nebraska the third known state to take such action this year.
…
Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies. Grantees are exempt from the requirements, which take effect May 2.
J&J’s mid-day notice to customers
…
The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from
…
UPDATE Friday, March 18, 2022, 1:30 p.m. EDT—The U.S. Health Resources and Services Administration (HRSA) told 340B Report shortly after this story was published, “To be eligible, [a] hospital’s termination must have been as a result of actions taken by
…*Sign up for news summaries and alerts from 340B Report